Close
  Indian J Med Microbiol
 

Figure 1: Median progression-free survival in patients on lorlatinib of 9.0 months (range: 5.6–12.3 months)

Figure 1: Median progression-free survival in patients on lorlatinib of 9.0 months (range: 5.6–12.3 months)